Based on these results, the randomized phase III ALFA-0701 trial compared fractionated GO (3 mg/mq on days 1,4 and 7 during induction and on day 1 of each consolidation course) plus standard chemotherapy vs. chemotherapy alone in newly diagnosed CD33+ AML patients aged 50 to 70 years [47]. Here, CD33 is linked to acute myeloid leukemia.